Financial Highlights - Total revenue reached RMB 873 billion, down by 108% year-on-year, mainly impacted by Yuyuan revenue declining[8] - Overseas revenue accounted for 53% of total revenue, up by 7 percentage points year-on-year, reaching RMB 4667 billion[8] - Industrial operating profit slightly increased to RMB 315 billion, excluding the impact of Happiness Business[8] - Investment in Technology and Innovation was RMB 636 billion, with a stable share of total revenue at 73%[8] - Adjusted NAV was HKD 180 per share, totaling HKD 258 billion[8] - Public markets financing reached RMB 1362 billion, excluding consolidated subsidiaries[14] Business Segment Performance - Health segment revenue was RMB 2257 billion[50] - Happiness segment revenue was RMB 3372 billion, a decrease of 219% year-on-year[10, 95] - Intelligent Manufacturing segment revenue was RMB 402 billion[143] - Wealth segment revenue was RMB 2783 billion, up by 33% year-on-year[10, 134] Strategic Development and Globalization - Fosun Insurance Portugal's international business recorded premiums of EUR 924 million, nearly 30% of total[21] - Henlius' overseas product profits grew over 200% year-on-year[26] - Shede Spirits' overseas sales exceeded RMB 10 million, up by 35% year-on-year[26]

CHINA MENGNIU DAIRY COMPANY LIMITED (2319.HK) 2025 Interim Results Legal Disclaimer The presentation is prepared by China Mengniu Dairy Company Limited (the "Company") and is solely for the purpose of corporate communication and general reference only. The presentation is not intended as an offer to sell, or to solicit an offer to buy or to form any basis of investment decision for any class of securities of the Company in any jurisdiction. All such information should not be used or relied on without profes ...

Financial Performance - Gross Written Premiums reached RMB 52509 billion, a 73% increase[20] - Gross Investment Income increased to RMB 12751 billion, up by 42%[20] - Net Profit Attributable to Equity Holders of the Company grew to RMB 4093 billion, a 69% rise[20] - Embedded Value reached RMB 147783 billion, a 55% increase[20] - Total Assets amounted to RMB 729236 billion, a 77% increase[20] Business Operations - Value of Half Year's Sales for the individual agent channel increased by 95%, reaching RMB 24337 million[29] - First-year Regular Bancassurance Business premiums increased by 457%, reaching RMB 36571 million[35] - Digital underwriting specialists drove intelligent approval rate of underwriting to 958%[37] Investment Portfolio - Fixed-maturity Financial Assets accounted for 7356% of the investment portfolio, totaling RMB 5242536 million[45] - Equity Financial Assets represented 2000% of the portfolio, amounting to RMB 1425659 million[45] - Over 98% of the credit bonds held by the company were rated AAA[53] Solvency - Comprehensive Solvency Ratio stood at 19094%[20]

Financial Performance - The company's total revenue increased by 14.3% to RMB 38.54 billion [3, 50] - Profit attributable to equity shareholders increased by 14.5% to RMB 7.03 billion [6, 96] - The company's overall gross profit margin was 63.4%, a 0.7 percentage point decrease [54] - Free cash inflow amounted to RMB 7.55 billion [7] - The company declared an interim dividend per share of HK 137 cents, a 16.1% increase [71, 96] Brand Performance - ANTA brand revenue increased by 5.4% to RMB 16.95 billion [3, 52] - FILA brand revenue increased by 8.6% to RMB 14.18 billion [3, 52] - All other brands revenue increased significantly by 61.1% to RMB 7.41 billion [3, 52] E-commerce and Digitalization - E-commerce revenue increased by 17.6% year-over-year [35] - E-commerce contributed 34.8% to the Group's overall revenue, compared to 32.8% in the first half of 2024 [37] Market Review - Total Retail Sales of Consumer Goods increased by 5.0% from January to June 2025 [12] - The Consumer Confidence Index in June 2025 was 87.9 [12]

Financial Performance - The company's total revenue increased by 6.5% year-over-year to RMB 8.524 billion[13] - Core net profit grew by 15.0% year-over-year to RMB 2.011 billion[13] - The interim dividend per share increased by 89.6% year-over-year to RMB 0.529, and a special dividend of RMB 0.352 per share was declared[10, 28] Commercial Management Business - Revenue from the commercial management business increased by 14.6% year-over-year to RMB 3.267 billion[17] - Gross profit margin for the commercial management business increased by 5.2 percentage points year-over-year to 66.1%[17] - Retail sales of shopping malls grew by 21.1% year-over-year, reaching RMB 122.0 billion[10] Property Management Business - Revenue from the property management business increased by 1.1% year-over-year to RMB 5.157 billion[21] - Newly acquired contracted third-party areas totaled 14.32 million square meters, with urban space projects contributing 71.2%[10] - Customer satisfaction in property management reached 92.06 points, an increase of 0.3 points compared to the end of 2024[10, 82] Strategic Development - The total GFA under management reached 420 million square meters, an increase of 1.8% compared to the end of 2024[10, 70] - The number of commercial members exceeded 65 million, representing a 32% year-over-year increase[45]

Financial Performance - Revenue remained flat year-over-year at RMB6644 million[9,46] - Adjusted net profit decreased by 61% year-over-year to RMB1022 million, attributed to pricing decreases and marketing expenses[9,46] - Overseas sales increased by 40% year-over-year, reaching RMB1624 million, representing 244% of total sales[11,46] - R&D expenses reached RMB320 million, accounting for 47% of revenue[11] Business Segments - General medical device segment revenue was RMB3300 million, flat year-over-year, with a profit of RMB490 million, down by 171%[16] - Pharma packaging segment revenue was RMB1170 million, flat year-over-year, with a profit of RMB450 million, down by 58%[24] - Orthopaedics segment revenue was RMB730 million, slightly down by 16% year-over-year, but profit increased significantly by 743% to RMB150 million[27] - Blood management segment revenue increased by 81% year-over-year to RMB450 million, while profit decreased by 53% to RMB31 million[37] Strategic Initiatives - The company plans to maintain a dividend payout ratio at 50%[52] - Total production capacity for blood bags is expected to exceed 100 million units in 2025[37] - Auto injectors recorded strong sales in China, with H1 sales up by approximately 200%, accounting for approximately 3% of segment sales[24]

Financial Performance - Core profit reached RMB 3.22 billion, with domestic businesses contributing RMB 3.1 billion, a year-over-year increase of 0.7%[3] - Retail gas sales volume increased by 1.9% year-over-year to 12.95 billion m3[3] - Gross profit of the IE business increased by 2.1% year-over-year to RMB 1.09 billion[3] - Gross profit of the smart home business increased by 4.9% year-over-year to RMB 1.47 billion[3] - Revenue increased by 2.0% to RMB 55.673 billion[6] - Profit attributable to shareholders decreased by 5.6% to RMB 2.429 billion[6] Business Development - Newly installed designed daily capacity for C/I customers reached 6.29 million m3, and 692,000 residential household customers were newly developed[3] - Installed capacity of photovoltaic increased by 231% year-over-year to 324.5 MW[3] - Contracted value of intelligent products in the smart home business increased by 81% year-over-year to RMB 553 million[3] Strategic Initiatives - The company is focusing on customer needs and upgrading products and services to increase contributions from integrated energy and smart home businesses[5] - The company is actively promoting the integrated energy concept and accelerating PV and energy storage deployment[12] - The company is identifying customer needs in security services and creating an integrated model for value-added services in the smart home business[14] Dividend - The company declares an interim dividend of HK$0.65 per share[3]

Innovent Biologics 2025 Interim Results Advancing toward a New Era of Growth and Global Innovation August 2025 Agenda and Speakers | Business Review and Outlook | Dr. Michael Yu | Founder, Chairman of the Board, CEO | | --- | --- | --- | | R&D Highlight Updates | Dr. Hui Zhou Dr. Lei Qian | Chief R&D Officer, Oncology Chief R&D Officer, General Biomedicine | | Financials and Summary | Ms. Rachel You | Chief Financial Officer | | Q&A | Management Team | | Confidential Copyright© 2025 Innovent 2025H1: Continu ...

Financial Performance - The Group's revenue reached RMB 500.1 billion, a 1.0% year-over-year increase[11] - OPAT (Operating Profit After Tax) grew by 3.7% year-over-year to RMB 77.7 billion[13] - Shareholders' equity increased by 1.7% YTD (Year-to-Date) after dividend distribution, reaching RMB 944 billion[13] - Interim dividend per share (DPS) increased by 2.2% year-over-year to RMB 0.95[13] - NBV (New Business Value) for Life & Health (L&H) grew significantly by 39.8% year-over-year[15] Business Segments - P&C (Property & Casualty) premium income increased by 7.1% year-over-year to RMB 171.9 billion[15] - P&C insurance revenue grew by 2.3% year-over-year to RMB 165.7 billion[15] - The P&C Combined Operating Ratio (COR) improved by 2.6 percentage points year-over-year to 95.2%[15] - Bank net profit amounted to RMB 24.9 billion with a NPL ratio of 1.05%[16] Customer Engagement - Retail customers increased by 1.8% YTD to 247 million[13] - 26.6% of retail customers hold 4+ contracts, with a 97.8% retention rate[13] Investment - Unannualized comprehensive investment yield was 3.1%, up 0.3 percentage points year-over-year[16] - Insurance funds grew 8.2% YTD to RMB 6.2 trillion[25]

2025 Interim Results Investor Presentation August 2025 Contents 1. Results Highlights 5. ESG Development 2. Scale & Profitability Strengths 6. Outlook 3. Financial Stability Strengths 7. Appendices 4. Competitive Development Strengths Beijing | Corniche 1. Results Highlights 2025 Interim Results Highlights Sales remained among the top in the industry Contracted sales 120.15b Leading sales scale in first-tier cities Contracted sales in Hong Kong, Beijing, Shanghai, Guangzhou and Shenzhen 55.64b Leading marke ...